Antinuclear antibodies are common and linked to poor response to omalizumab treatment in patients with CSU. Issue 2 (3rd October 2019) - Ertaş, Ragıp; Hawro, Tomasz; Altrichter, Sabine; Özyurt, Kemal; Erol, Kemal; Ketenci Ertaş, Şule; Maurer, Marcus